Document is current
Any future updates will be listed below
-
Authors
Mascarenhas, John https://orcid.org/0000-0002-8400-0483
Gerds, Aaron https://orcid.org/0000-0002-3422-1309
Verstovsek, Srdan https://orcid.org/0000-0002-6912-8569
- License Information
-
More Information
Article History
Received: 10 July 2021
Revised: 16 August 2021
Accepted: 26 August 2021
First Online: 3 September 2021
Competing interests
: JM has received research support paid to his institution from PharmaEssentia, Abbvie, CTI Bio, Merck, Roche, Novartis, BMS, Forbius, Kartos, Incyte, Geron, Sierra Oncology; consulting or advisory board fees from Kartos, CTI Bio, Constellation, Incyte, Roche, Novartis, BMS, Abbvie, PharmaEssentia, and Geron. AG has received advisory board fees from PharmaEssentia, BMS, Novartis, AbbVie, Sierra Oncology. SV has received research support paid to his institution from Incyte, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Protagonist, Kartos; advisory board fees from Constellation, BMS, Sierra Oncology, Incyte, Novartis, Celgene, PharmaEssentia.
